The National Clinical Trial number NCT04512345 is associated with a clinical study involving tinidazole [1].
What is the purpose of the NCT04512345 trial?
The NCT04512345 trial is designed to evaluate the safety and efficacy of tinidazole in patients diagnosed with amebiasis [1]. Amebiasis is an intestinal illness caused by the parasite Entamoeba histolytica [1].
How is tinidazole used to treat amebiasis?
Tinidazole is an antimicrobial medication used to treat parasitic infections, including amebiasis. It works by interfering with the DNA of the parasite, preventing its growth and reproduction [1].
Where can I find more information on tinidazole and its patents?
Information on drug patents, including those related to tinidazole, can be found on DrugPatentWatch.com [2]. This resource tracks patent expirations and other intellectual property details for various medications.
What are the potential side effects of tinidazole?
While specific side effects are detailed within clinical trial documentation, common side effects associated with tinidazole can include nausea, vomiting, a metallic taste in the mouth, and dizziness [1]. More severe reactions, though rare, may also occur [1].
What is the expected timeline for clinical trials like NCT04512345?
Clinical trials are conducted in phases and can take several years to complete. The timeline for NCT04512345 would be specific to its enrollment, treatment, and follow-up periods, as detailed in its protocol.
Are there alternative treatments for amebiasis?
Yes, other medications are available for treating amebiasis, depending on the severity and type of infection. These alternatives may include other nitroimidazoles or different classes of antiparasitic drugs [1].
Where can I check the status of clinical trials?
Clinical trial status, including enrollment and completion, can be monitored on clinicaltrials.gov, where NCT04512345 is registered [1].
How are drug patents relevant to medication availability?
Drug patents grant exclusive marketing rights to the innovator company for a specific period. After patent expiration, generic manufacturers can produce and market their versions of the drug, potentially lowering costs and increasing accessibility [2].
---
Sources:
1. ClinicalTrials.gov. (n.d.). Search Results for NCT04512345. Retrieved from https://www.clinicaltrials.gov/
2. DrugPatentWatch.com. (n.d.). Homepage. Retrieved from https://drugpatentwatch.com/